Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
April 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 |
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Press releases published on March 26, 2025
Melbourne Pharma Opens Doors April 1st
EIN Presswire
·
March 26, 2025
Melbourne Pharma opens April 1st in Melbourne, FL, offering cutting edge compounding medications for dermatology, weight management, and wellness. MELBOURNE, FL, UNITED STATES, March 26, 2025 /EINPresswire.com/ -- Melbourne Pharma, a state-of-the-art …
NovaCHARGE Named Preferred Vendor for a Major Florida Hospital System, Providing Reliable EV Charging Solutions
EIN Presswire
·
March 26, 2025
NovaCHARGE Selected as Preferred Vendor for Florida Hospital System, Offering Reliable EV Charging Solutions ORLANDO, FL, UNITED STATES, March 26, 2025 /EINPresswire.com/ -- NovaCHARGE, a leader in providing electric vehicle (EV) charging infrastructure …
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
GlobeNewswire
·
March 26, 2025
SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the …
Alvotech Reports Record Results for 2024 and Provides Business Update
GlobeNewswire
·
March 26, 2025
Total Revenues in 2024 reached $492 million, representing a 427% increase over prior year Product Revenues in 2024 reached $273 million, representing a 462% increase over prior year Adjusted EBITDA in 2024 was $108.3 million compared to negative $291 …
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
GlobeNewswire
·
March 26, 2025
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ( …
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
GlobeNewswire
·
March 26, 2025
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris …
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
GlobeNewswire
·
March 26, 2025
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission KANSAS CITY, Kan., March 26, 2025 (GLOBE …
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
GlobeNewswire
·
March 26, 2025
Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on …
AquaSculpt Reviews (BREAKTHROUGH REPORT): Why Thousands Are Trying This Cold Activation Method to Burn Fat In 2025
GlobeNewswire
·
March 26, 2025
Seattle, March 26, 2025 (GLOBE NEWSWIRE) -- Aquasculpt The weight loss industry is flooded with fads, gimmicks, and overhyped miracle cures that promise dramatic transformations yet fail to deliver. But AquaSculpt reviews are taking the internet by storm, …
BioCardia Reports 2024 Business Highlights and Financial Results
GlobeNewswire
·
March 26, 2025
SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended …
Tilray Successfully Prevails with Dismissal of HEXO Shareholder Lawsuit
GlobeNewswire
·
March 26, 2025
NEW YORK and LEAMINGTON, Ontario, March 26, 2025 (GLOBE NEWSWIRE) -- Tilray Brands Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), and its subsidiary HEXO Corporation (“HEXO”), announced the successful dismissal of the Clement Italume vs. Robinhood Markets Inc …
Solésence Reports Record Fourth Quarter and Full-Year 2024 Financial Results
GlobeNewswire
·
March 26, 2025
Fourth quarter revenue increased 58% to a record $12.6 million Full Year 2024 revenue increased 40% to a record $52.3 million ROMEOVILLE, Ill., March 26, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care …
Prime Biome Reviews (URGENT ALERT) Users Expose Facts About The Digestive Side Effects & Benefits You Haven’t Heard Yet
GlobeNewswire
·
March 26, 2025
Seattle, March 26, 2025 (GLOBE NEWSWIRE) -- Prime Biome Gut health and skin care have always been treated as separate issues, with people relying on skincare products for clearer skin and digestive aids for bloating or discomfort. But what if the secret …
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
GlobeNewswire
·
March 26, 2025
WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved …
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results
GlobeNewswire
·
March 26, 2025
On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our next generation targeted radiopharmaceutical technology …
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
GlobeNewswire
·
March 26, 2025
Experimental treatment with CAN-2409 was associated with a median overall survival (mOS) of 24.5 months in patients with advanced NSCLC who had an inadequate response to ICI treatment, failed several chemotherapy regimens, and presented with multiple …
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
GlobeNewswire
·
March 26, 2025
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team …
Dyadic Reports 2024 Year-End Financial Results and Business Updates
GlobeNewswire
·
March 26, 2025
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024 Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture …
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
GlobeNewswire
·
March 26, 2025
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence – - Both groups demonstrated comparable weight loss with less …
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire
·
March 26, 2025
PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a …